Bull
$329.90
Szenariopreis
$194.350
+4.081 (+2.10%)Zum Schluss
Equifax Inc. is a global data, analytics, and technology company. The Company is engaged in helping financial institutions, companies, employers, and government agencies make critical decisions. The Company’s Workforce Solutions segment provides services enabling customers to verify income, employment, educational history, criminal justice data, healthcare professional licensure and sanctions of people in the United States. The Company’s U.S. Information Solutions (USIS) segment provides consumer and commercial information solutions to businesses in the United States, including online information, decisioning technology solutions, identity management services, analytical services, e-commerce fraud and charge back protection services, portfolio management services, mortgage information and marketing services. The Company’s International segment provides products and services similar to those available in the USIS segment but with variations by geographic region.
Equifax Inc is a good buy right now, trading at $194.35 with a forward P/E of 22.57, indicating potential for growth. The RSI is at 68.35, suggesting it is nearing overbought territory but still has momentum. The recent analyst upgrades highlight confidence in Equifax's growth potential, particularly with a target of $235 from Rothschild & Co, which is a 20.9% upside from the current price. However, a key risk is the declining Government Verification revenue, which fell by 4% in Q2, indicating potential headwinds.
Rothschild & Co Redburn
$235
2026-08-21
Rothschild & Co Redburn
2026-08-21
Kursziel
$235
Deutsche Bank
$208
2026-07-22
Deutsche Bank
2026-07-22
Kursziel
$208
BofA
$210
2026-07-22
BofA
2026-07-22
Kursziel
$210
Wells Fargo
$212
2026-07-22
Wells Fargo
2026-07-22
Kursziel
$212
Clear Street
$190
2026-07-22
Clear Street
2026-07-22
Kursziel
$190
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Canadian Consumer Debt Continues to Rise

Equifax Declares Quarterly Dividend of $0.56 Per Share

Equifax Declares Quarterly Dividend of $0.56

Equifax Surpasses Amcor to Become #375 in S&P 500

Equifax to Participate in Multiple Upcoming Investor Conferences
Equifax Inc. is a global data, analytics, and technology company. The Company is engaged in helping financial institutions, companies, employers, and government agencies make critical decisions. The Company’s Workforce Solutions segment provides services enabling customers to verify income, employment, educational history, criminal justice data, healthcare professional licensure and sanctions of people in the United States. The Company’s U.S. Information Solutions (USIS) segment provides consumer and commercial information solutions to businesses in the United States, including online information, decisioning technology solutions, identity management services, analytical services, e-commerce fraud and charge back protection services, portfolio management services, mortgage information and marketing services. The Company’s International segment provides products and services similar to those available in the USIS segment but with variations by geographic region. It operates in the Industrials sector (SERVICES-CONSUMER CREDIT REPORTING, COLLECTION AGE industry).
Equifax Inc is a good buy right now, trading at $194.35 with a forward P/E of 22.57, indicating potential for growth. The RSI is at 68.35, suggesting it is nearing overbought territory but still has momentum. The recent analyst upgrades highlight confidence in Equifax's growth potential, particularly with a target of $235 from Rothschild & Co, which is a 20.9% upside from the current price. However, a key risk is the declining Government Verification revenue, which fell by 4% in Q2, indicating potential headwinds.
16 analysts cover EFX: 10 rate it Buy, 6 Hold and 0 Sell. The average price target is 232.08.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.